HRP Streptavidin

Catalog# / Size	405210 / 1 mL
Regulatory Status	RUO
Other Names	Streptavidin-Horseradish Peroxidase, SAv-HRP
Description	Streptavidin binds to biotin with high affinity. Streptavidin-HRP is useful for detecting biotinylated antibodies, *e.g.*, in ELISA, ELISPOT, IHC or Western blotting. For ELISA applications, HRP will act on soluble substrates, such as ABTS or TMB, to yield a colorimetric reaction. For ELISPOT or Western blotting applications, HRP will act on precipitating substrates, such as 4CN, to yield a colorimetric reaction.

Product Details

Verified Reactivity	Human, Mouse, Rat, All Species
Formulation	Buffered solution containing bovine protein and preservatives (methylisothiazolone, bromonitrodioxane, and other active isothiazolones).
Preparation	Streptavidin is conjugated with horseradish peroxidase under optimal conditions.
Storage & Handling	The streptavidin-HRP solution should be stored undiluted between 2°C and 8°C. **Avoid exposure to sodium azide.** To obtain lot-specific expiration date, please enter the lot number in our Concentration and Expiration Lookup or Certificate of Analysis online tools.) This product has a shelf-life of 12 months or less. Please use our Expiration Lookup Tool to verify the expiration date of your lot of product
Application	ELISA - Quality tested ELISPOT, WB, IHC - Reported in the literature, not verified in house
Recommended Usage	Each lot of this Streptavidin-HRP is quality control tested by ELISA assay. For ELISA or Western blot analysis, the reagent should be titrated between 1:1000 - 1:3000 to determine optimal conditions. For ELISPOT analysis, the reagent should be titrated between 1:500 - 1:1500 to determine optimal conditions. Avoid using biotin-containing solutions as diluents and solutions containing sodium azide. Sodium azide is an inhibitor of horseradish peroxidase. It is recommended that the reagent be titrated for optimal performance for each application.
Application Notes	Streptavidin-HRP is useful as a second step reagent for indirect enzymatic labelling, in conjunction with biotinylated primary antibodies. Sav-HRP is recommended for ELISA, ELISPOT and Western blotting, when used with the relevant substrate system.

Application References

(PubMed link indicates BioLegend citation)

1. Li KJ, *et al.* 2006. *J. Leukoc. Biol.* doi:10.1189/jlb.1105668.PubMed
2. Weldon S, *et al.* 2009. *J. Immunol.* 183:8148. PubMed
3. Basnayake K, *et al.* 2010. *J Am Soc Naphrol.* 21:1165. PubMed
4. Marder W, *et al.* 2011. *Ann Rheum Dis.* PubMed
5. Cheng J, *et al.* 2012. *Mol Biol Cell.* 23:2891. PubMed
6. Vishwakarma V, *et al.* 2012. *Infect Immun.* 80:3236. PubMed
7. Sun X, *et al.* 2013. *J. Immunol.* 190:2536. PubMed
8. Van Phan T, *et al.* 2013. *Biochem Pharmacol.* 85:1145. PubMed
9. Ranganathan P, *et al.* 2013. *J Rhematol.* 40:129. PubMed
10. Din Su, *et al.* 2013. *Occup Med.* PubMed
11. Bulut GB, *et al.* 2013. *Blood.* 122:3964. PubMed
12. Chia YL, *et al.* 2013. *Antiviral Res.* 3542:354. PubMed
13. Ahn JM, *et al.* 2014. *Mol Cell Proteomics.* 13:30. PubMed
14. Din SU, *et al.* 2014. *Occup Med.* 64:39. PubMed
15. Balmer ML, *et al.* 2014. *Sci Transl Med.* 21:237. PubMed
16. Klehmet J, *et al.* 2014. *J Neurol Neurosurg Psychiatry.* PubMed
17. Wu CC, *et al.* 2014. *Cancer Epidemiol. Biomarkers Prev.* 23:1569. PubMed
18. Peng JG, *et al.* 2014. *J Virol.* 88:8386. PubMed
19. Chlon TM, *et al.* 2014. *J Virol.* 88:11315. PubMed
20. Sadovskaya I, *et al.* 2014. *Carbohydr Poly.* 111:139. PubMed
21. Liu T, *et al.* 2015. *Infect Immun.* 83:2011. PubMed

22. Himmelein S, *et al.* 2015. *J Virol.* 89:5747. PubMed
23. Dinter J, *et al.* 2015. *J Mol Endocrinol.* 54:205. PubMed
24. Yang L, *et al.* 2015. *J Immunol.* 194:5635. PubMed

Product Citations

1. Zhang C, *et al.* 2015. J Surgical Res. 197: 301-306. PubMed
2. Lin C, *et al.* 2020. Cancer Immunol Res. 632:8. PubMed
3. Wang YH, *et al.* 2018. Oncol Lett. 16:6903. PubMed
4. Csobán-Szabó Z, *et al.* 2021. Int J Mol Sci. 22:. PubMed
5. Lopez-Gordo E, *et al.* 2022. Front Med (Lausanne). 8:732095. PubMed
6. Tabynov K, *et al.* 2022. NPJ Vaccines. 7:24. PubMed
7. Clemente V, *et al.* 2022. Cancer Res Commun. 2:784. PubMed
8. Watanabe T, *et al.* 2020. Cytotherapy. . PubMed
9. Gendron D, *et al.* 2017. Pulm Pharmacol Ther. 10.1016/j.pupt.2017.03.010. PubMed
10. Kongsuphol P, *et al.* 2022. Commun Med (Lond). 1:46. PubMed
11. Cheng J, *et al.* 2012. Mol Biol Cell. 23:2891. PubMed
12. Tu S, *et al.* 2015. Nature. 534:387-390. PubMed
13. Brugiroux S, *et al.* 2016. Nat Microbiol. 2:16215. PubMed
14. Kikuchi N, *et al.* 2019. Biol Pharm Bull. 42:57. PubMed
15. Li Q, *et al.* 2020. Cell Stem Cell. 675:26. PubMed
16. Himmelein S, *et al.* 2015. J Virol. 89:5747. PubMed
17. Ahn J, *et al.* 2014. Mol Cell Proteomics. 13:30. PubMed
18. Gamache J, *et al.* 2019. Nat Commun. 10:2479. PubMed
19. Hooper K, Kong W, Ganea D, *et al.* 2017. PLoS One. 12(6):e0179184. PubMed
20. Castellanos CA, *et al.* 2021. Sci Immunol. 6:eabh0707. PubMed
21. Fan X, *et al.* 2021. Int J Mol Sci. 22:. PubMed
22. Wu J 2014. J Virol. 88:8386. PubMed
23. Cárdenas–Torres FI, *et al.* 2019. Medicina (Kaunas). 55:3. PubMed
24. Duan S, *et al.* 2019. J Clin Invest. 129:1387. PubMed
25. Sielemann J, *et al.* 2021. Nat Commun. 12:6549. PubMed
26. Hwang D, *et al.* 2016. PLoS One. 11: 0152522. PubMed
27. Marder W, *et al.* 2011. Ann Rheum Dis. 70:1550. PubMed
28. Li K, *et al.* 2006. J Leukoc Biol . 80:350. PubMed
29. Asarnow D, *et al.* 2021. Cell. 184:3192. PubMed
30. Vishwakarma V, *et al.* 2012. Infect Immun . 80:3236. PubMed
31. Nakanishi M, *et al.* 2019. Cell. 177:910. PubMed
32. Czakai K, *et al.* 2016. Sci Rep. 6:27990. PubMed
33. Weldon S, *et al.* 2009. J Immunol. 183:8148. PubMed
34. Duan S, *et al.* 2021. J Immunol. 206:2290. PubMed
35. Phillips AT, *et al.* 2021. Invest Ophthalmol Vis Sci. 62:15. PubMed
36. Counoupas C, *et al.* 2020. NPJ Vaccines. 0.28125. PubMed
37. Peng Y 2017. PLoS One. 10.1371/journal.pone.0188112. PubMed
38. Morita M, *et al.* 2021. Heliyon. 7:e06228. PubMed
39. MÜller A, *et al.* 2016. PLoS One. 11:e0168260. PubMed
40. Tidley S 2014. Occup Med. 64:39. PubMed
41. Ye F, *et al.* 2016. J Virol. 90: 9654 - 9663. PubMed
42. Crowley SJ, *et al.* 2020. Open Biol. 10:190235. PubMed
43. Morgan R, *et al.* 2016. PLoS One. 11: 0162008. PubMed
44. Chlon T, *et al.* 2014. J Virol. 88:11315. PubMed
45. Tuladhar R, *et al.* 2019. J Biol Chem. 294:6273. PubMed
46. Gröschel C, *et al.* 2017. Sci Rep.. 10.1038/s41598-017-16147-1. PubMed
47. Tsukamoto H, *et al.* 2017. FEBS Lett. 10.1002/1873-3468.12768. PubMed
48. Shukla SP, *et al.* 2021. Int J Mol Sci. 22:. PubMed
49. Simic MS, *et al.* 2019. Sci Adv. 5:eaaw0025. PubMed
50. Herp S, *et al.* 2019. Cell Host Microbe. 25:681. PubMed
51. Vijver SV, *et al.* 2021. Front Immunol. 12:733561. PubMed
52. Cildag S, *et al.* 2021. Med Pharm Rep. 94:53. PubMed
53. Bello A, *et al.* 2021. Immunol Cell Biol. 99:879. PubMed
54. Klehmet J, *et al.* 2014. J Neurol Psychiatry. . PubMed
55. Chia Y, *et al.* 2013. Antiviral Res. 3542:354. PubMed
56. Bulut G, *et al.* 2013. Blood. 122:3964. PubMed
57. den Hartigh AB, *et al.* 2018. Curr Protoc Immunol. :e52. PubMed
58. Clemente V, *et al.* 2021. Cells. 10: . PubMed
59. Yen J, *et al.* 2015. J Leukoc Biol. 98: 689-702. PubMed
60. Ozawa T, *et al.* 2021. iScience. 24:102488. PubMed
61. Sinha D, *et al.* 2020. Anal Biochem. 113827:608. PubMed
62. Tsanov K, *et al.* 2016. Nat Cell Biol. 19:60-67. PubMed
63. Baerenwaldt A, *et al.* 2016. J Immunol. 196: 2561 - 2571. PubMed
64. Dinter J, *et al.* 2015. J Mol Endocrinol. 54:205. PubMed
65. Makowski EK, *et al.* 2021. MAbs. 13:1951426. PubMed
66. Sun X, *et al.* 2013. J Immunol. 190:2536. PubMed
67. Balmer M, *et al.* 2014. Sci Transl Med. 21:237. PubMed
68. Wu C, *et al.* 2014. Cancer Epidemiol Biomarkers Prev. 23:1569. PubMed
69. Kiriakidis S, *et al.* 2017. Kidney International. 10.1016/j.kint.2017.03.008. PubMed
70. Basnayake K, *et al.* 2010. J Am Soc Nephrol. 1.684027778. PubMed
71. Kim DJ, *et al.* 2020. Proc Natl Acad Sci U S A. 117:15837. PubMed
72. Parrish H, *et al.* 2016. Proc Natl Acad Sci U S A. 113: 3000 - 3005. PubMed
73. Ugurlu-Çimen D, *et al.* 2021. Epigenetics Chromatin. 14:32. PubMed
74. Phan T, *et al.* 2013. Biochem Pharmacol. 85:1145. PubMed

75. Sadovskaya I, *et al.* 2014. Carbohydr Polym. 111:139. PubMed
76. Xing QR, *et al.* 2020. Sci Adv. 6:00. PubMed
77. von Wenserski L, *et al.* 2020. Leukemia. . PubMed
78. Isernhagen A, *et al.* 2015. EMBO Mol Med. 7: 1480 - 1502. PubMed
79. Shinohara M 2015. J Immunol. 194:5635. PubMed
80. Liu T, *et al.* 2015. Infect Immun . 83:2011. PubMed
81. Gröschel C, *et al.* 2018. Front Immunol. 9:2665. PubMed
82. Buschor S, *et al.* 2017. PLoS Pathogens. 13(6):e1006476. PubMed

Antigen Details

Gene ID NA

Related Protocols

Sandwich ELISA Protocol

BioLegend Inc., 8999 BioLegend Way, San Diego, CA 92121 www.biolegend.com
Toll-Free Phone: 1-877-Bio-Legend (246-5343) Phone: (858) 768-5800 Fax: (877) 455-9587